{"Abstract": [0], "Integrins": [1], "are": [2, 42, 127], "considered": [3], "the": [4, 68, 74, 90, 222, 230, 240], "main": [5], "cell-adhesion": [6], "transmembrane": [7], "receptors": [8], "that": [9, 172], "play": [10], "multifaceted": [11], "roles": [12], "as": [13, 81], "extracellular": [14], "matrix": [15], "(ECM)-cytoskeletal": [16], "linkers": [17], "and": [18, 22, 27, 38, 50, 61, 71, 94, 123, 168, 183, 192, 200, 239, 248], "transducers": [19], "in": [20, 30, 36, 138], "biochemical": [21], "mechanical": [23], "signals": [24], "between": [25, 48], "cells": [26], "their": [28, 65], "environment": [29], "a": [31, 45, 103, 177, 190], "wide": [32], "range": [33], "of": [34, 92, 131, 180, 195, 224, 233], "states": [35], "health": [37], "diseases.": [39], "Integrin": [40], "functions": [41], "dependable": [43], "on": [44, 67, 175], "delicate": [46], "balance": [47], "active": [49], "inactive": [51], "status": [52], "via": [53], "multiple": [54], "mechanisms,": [55], "including": [56, 116, 141], "protein-protein": [57], "interactions,": [58], "conformational": [59], "changes,": [60], "trafficking.": [62], "Due": [63], "to": [64, 73, 205, 209, 215, 228], "exposure": [66], "cell": [69], "surface": [70], "sensitivity": [72], "molecular": [75], "blockade,": [76], "integrins": [77, 93, 111], "have": [78, 112], "been": [79, 102, 113], "investigated": [80], "pharmacological": [82], "targets": [83], "for": [84, 243], "nearly": [85], "40": [86], "years,": [87], "but": [88], "given": [89], "complexity": [91], "sometimes": [95], "opposite": [96], "characteristics,": [97], "targeting": [98, 110, 236], "integrin": [99, 165, 197, 237], "therapeutics": [100], "has": [101], "challenge.": [104], "To": [105], "date,": [106], "only": [107], "seven": [108], "drugs": [109, 134], "successfully": [114], "marketed,": [115], "abciximab,": [117], "eptifibatide,": [118], "tirofiban,": [119], "natalizumab,": [120], "vedolizumab,": [121], "lifitegrast,": [122], "carotegrast.": [124], "Currently,": [125], "there": [126], "approximately": [128], "90": [129], "kinds": [130], "integrin-based": [132], "therapeutic": [133], "or": [135], "imaging": [136, 157], "agents": [137], "clinical": [139, 185, 234, 244], "studies,": [140], "small": [142], "molecules,": [143], "antibodies,": [144], "synthetic": [145], "mimic": [146], "peptides,": [147], "antibody\u2013drug": [148], "conjugates": [149], "(ADCs),": [150], "chimeric": [151], "antigen": [152], "receptor": [153], "(CAR)": [154], "T-cell": [155], "therapy,": [156], "agents,": [158], "etc.": [159], "A": [160], "serious": [161], "lesson": [162], "from": [163, 213], "past": [164], "drug": [166, 225], "discovery": [167], "research": [169], "efforts": [170, 208], "is": [171], "successes": [173], "rely": [174], "both": [176], "deep": [178], "understanding": [179], "integrin-regulatory": [181], "mechanisms": [182], "unmet": [184], "needs.": [186], "Herein,": [187], "we": [188, 219], "provide": [189], "systematic": [191], "complete": [193], "review": [194], "all": [196], "family": [198], "members": [199], "integrin-mediated": [201], "downstream": [202], "signal": [203], "transduction": [204], "highlight": [206], "ongoing": [207], "develop": [210], "new": [211], "therapies/diagnoses": [212], "bench": [214], "clinic.": [216], "In": [217], "addition,": [218], "further": [220], "discuss": [221], "trend": [223], "development,": [226], "how": [227], "improve": [229], "success": [231], "rate": [232], "trials": [235], "therapies,": [238], "key": [241], "points": [242], "research,": [245, 247], "basic": [246], "translational": [249], "research.": [250]}